<DOC>
	<DOCNO>NCT00152620</DOCNO>
	<brief_summary>The aim therapeutic trial compare response subject active IBD daily intravenous dexamethasone versus response daily intravenous methylprednisolone .</brief_summary>
	<brief_title>Dexamethasone Versus Methylprednisolone Treatment Active Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Parental inform consent Subjects 6 19 year age confirm diagnosis IBD ( Crohn 's disease , ulcerative colitis indeterminate colitis ) , admission hospital PCDAI &gt; 15 ClinicalActivity Index Evaluation Patients Ulcerative Colitis &gt; 10 . Infectious cause ( virus , bacteria , parasite ) rule . Subjects administration corticosteroid would contraindicate systemic enteric infection diagnose stool analysis include culture , Clostridium Difficile toxin assay , rotavirus adenovirus 40/41 antigen . Subjects enterostomy colostomy Subjects one follow condition : unstable vital sign , acute abdomen , toxic megacolon , intestinal obstruction , intestinal perforation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Inflammatory Bowel Disease ( IBD )</keyword>
</DOC>